<p>Adicet Bio, Inc. (NASDAQ:ACET - 获取免费报告) 在四月份的空头头寸出现了显著下降。截至 4 月 15 日，空头头寸总计为 2,060,000 股，比 3 月 31 日的 2,850,000 股下降了 27.7%。目前，该公司的 3.1% 股份被做空。根据 796,900 股的平均日交易量，当前的覆盖天数比率为 2.6 天。</p>
<h2>机构资金流入和流出</h2>
<p>几家机构投资者最近对该公司的持仓进行了调整。Virtu Financial LLC 在第四季度购买了价值 29,000 美元的 Adicet Bio 新股份。Wealthedge Investment Advisors LLC 在第四季度购买了约 71,000 美元的 Adicet Bio 新股份。摩根大通在第三季度将其在 Adicet Bio 的持股增加了 10,321.9%。摩根大通目前拥有 80,353 股该公司的股票，价值 116,000 美元，此前在上个季度又购买了 79,582 股。北方信托公司在第四季度将其在 Adicet Bio 的持股增加了 25.1%。北方信托公司目前拥有 140,369 股该公司的股票，价值 135,000 美元，此前在上个季度又购买了 28,153 股。最后，Squarepoint Ops LLC 在第四季度购买了价值约 177,000 美元的 Adicet Bio 新股份。机构投资者持有该公司 83.89% 的股票。</p>
<h2>Adicet Bio 股票表现</h2>
<p>ACET 的股票在周四开盘价为 0.66 美元。Adicet Bio 的 52 周低点为 0.45 美元，52 周高点为 1.87 美元。该股票的 50 日简单移动平均线为 0.72 美元，200 日简单移动平均线为 0.94 美元。该股票的市值为 5475 万美元，市盈率为-0.39，贝塔值为 1.99。</p>
<p>Adicet Bio (NASDAQ:ACET - 获取免费报告) 最近于 3 月 6 日发布了季度财报。该公司报告本季度每股收益为（0.32 美元），超出分析师一致预期的（0.37 美元）0.05 美元。研究分析师平均预测 Adicet Bio 在当前财年将发布每股收益-1.39 美元。</p>
<h2>分析师设定新目标价</h2>
<p>多位研究分析师最近对 ACET 股票发表了评论。StockNews.com 在周一的研究报告中将 Adicet Bio 的评级从 “卖出” 上调至 “持有”。JMP Securities 在 2 月 6 日的报告中重申了 Adicet Bio 的 “市场表现” 评级。HC Wainwright 在 3 月 7 日的研究报告中重申了 Adicet Bio 的 “中性” 评级。最后，Guggenheim 在 3 月 21 日的研究报告中重申了 “买入” 评级，并设定了 7.00 美元的目标价。三位股票研究分析师对该股票给予了持有评级，三位则给予了买入评级。根据 MarketBeat 的数据，该股票的共识评级为 “适度买入”，共识目标价为 7.50 美元。</p>
<p><strong>阅读我们关于 Adicet Bio 的最新股票报告</strong></p>
<h2>Adicet Bio 公司简介</h2>
<p>(获取免费报告)</p>
<p>Adicet Bio, Inc.是一家临床阶段的生物技术公司，专注于发现和开发用于自身免疫疾病和癌症的异体伽马δ T 细胞疗法。该公司提供经过嵌合抗原受体（CARs）工程化的伽马δ T 细胞，以促进患者的持久活性。其主要产品候选药物是 ADI-001，一种表达针对 CD20 的 CAR 的异体伽马δ T 细胞疗法，目前正在进行针对自身免疫疾病和复发或难治性侵袭性 B 细胞非霍奇金淋巴瘤的 I 期临床试验。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票，胜过 Adicet Bio</li>
<li>顶尖生物技术股票：探索创新机会</li>
<li>D-Wave 与 Davidson 的项目为何是量子领域的游戏改变者</li>
<li>恒生指数是什么？</li>
<li>Hims &amp; Hers 股票因与诺和诺德的合作而飙升</li>
<li>三只小型股具有巨大的回报潜力</li>
<li>亚马逊的收益将决定股票的复苏成败</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Adicet Bio 吗？</h2>
<p>在你考虑 Adicet Bio 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Adicet Bio 并不在名单上。</p>
<p>虽然 Adicet Bio 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

ACET

<p>Adicet Bio, Inc.（纳斯达克代码：ACET）在空头头寸方面经历了显著下降，截至 4 月 15 日，下降了 27.7%，降至 2,060,000 股。目前，其 3.1% 的股份被做空，基于平均每日交易量 796,900 股，空头头寸比率为 2.6 天。机构投资者持有该股票的 83.89%，最近的活动包括 Virtu Financial 和 Wealthedge Investment Advisors 的新投资。分析师的评级意见不一，普遍评级为 “适度买入”，目标价格为 7.50 美元</p>

<p>Adicet Bio, Inc. (NASDAQ:ACET - Get Free Report) was the target of a significant drop in short interest during the month of April. As of April 15th, there was short interest totalling 2,060,000 shares, a drop of 27.7% from the March 31st total of 2,850,000 shares. Currently, 3.1% of the shares of the company are sold short. Based on an average daily trading volume, of 796,900 shares, the days-to-cover ratio is currently 2.6 days.</p>
<div class="lb-trans"><p>Adicet Bio, Inc. (NASDAQ:ACET - 获取免费报告) 在四月份的空头头寸出现了显著下降。截至 4 月 15 日，空头头寸总计为 2,060,000 股，比 3 月 31 日的 2,850,000 股下降了 27.7%。目前，该公司的 3.1% 股份被做空。根据 796,900 股的平均日交易量，当前的覆盖天数比率为 2.6 天。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Several institutional investors have recently made changes to their positions in the company. Virtu Financial LLC bought a new stake in Adicet Bio during the fourth quarter valued at $29,000. Wealthedge Investment Advisors LLC bought a new stake in shares of Adicet Bio during the 4th quarter valued at about $71,000. JPMorgan Chase &amp; Co. grew its holdings in shares of Adicet Bio by 10,321.9% during the third quarter. JPMorgan Chase &amp; Co. now owns 80,353 shares of the company's stock worth $116,000 after purchasing an additional 79,582 shares in the last quarter. Northern Trust Corp grew its holdings in shares of Adicet Bio by 25.1% during the fourth quarter. Northern Trust Corp now owns 140,369 shares of the company's stock worth $135,000 after purchasing an additional 28,153 shares in the last quarter. Finally, Squarepoint Ops LLC bought a new position in shares of Adicet Bio in the fourth quarter worth approximately $177,000. Institutional investors own 83.89% of the company's stock.</p>
<div class="lb-trans"><p>几家机构投资者最近对该公司的持仓进行了调整。Virtu Financial LLC 在第四季度购买了价值 29,000 美元的 Adicet Bio 新股份。Wealthedge Investment Advisors LLC 在第四季度购买了约 71,000 美元的 Adicet Bio 新股份。摩根大通在第三季度将其在 Adicet Bio 的持股增加了 10,321.9%。摩根大通目前拥有 80,353 股该公司的股票，价值 116,000 美元，此前在上个季度又购买了 79,582 股。北方信托公司在第四季度将其在 Adicet Bio 的持股增加了 25.1%。北方信托公司目前拥有 140,369 股该公司的股票，价值 135,000 美元，此前在上个季度又购买了 28,153 股。最后，Squarepoint Ops LLC 在第四季度购买了价值约 177,000 美元的 Adicet Bio 新股份。机构投资者持有该公司 83.89% 的股票。</p>
</div><h2>Adicet Bio Stock Performance</h2>
<div class="lb-trans"><h2>Adicet Bio 股票表现</h2>
</div><p>Shares of ACET opened at $0.66 on Thursday. Adicet Bio has a 52-week low of $0.45 and a 52-week high of $1.87. The stock's 50-day simple moving average is $0.72 and its 200 day simple moving average is $0.94. The stock has a market capitalization of $54.75 million, a price-to-earnings ratio of -0.39 and a beta of 1.99.</p>
<div class="lb-trans"><p>ACET 的股票在周四开盘价为 0.66 美元。Adicet Bio 的 52 周低点为 0.45 美元，52 周高点为 1.87 美元。该股票的 50 日简单移动平均线为 0.72 美元，200 日简单移动平均线为 0.94 美元。该股票的市值为 5475 万美元，市盈率为-0.39，贝塔值为 1.99。</p>
</div><p>Adicet Bio (NASDAQ:ACET - Get Free Report) last released its quarterly earnings data on Thursday, March 6th. The company reported ($0.32) EPS for the quarter, beating analysts' consensus estimates of ($0.37) by $0.05. On average, research analysts forecast that Adicet Bio will post -1.39 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Adicet Bio (NASDAQ:ACET - 获取免费报告) 最近于 3 月 6 日发布了季度财报。该公司报告本季度每股收益为（0.32 美元），超出分析师一致预期的（0.37 美元）0.05 美元。研究分析师平均预测 Adicet Bio 在当前财年将发布每股收益-1.39 美元。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>A number of research analysts have recently commented on ACET shares. StockNews.com raised Adicet Bio from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Monday. JMP Securities reaffirmed a &#34;market perform&#34; rating on shares of Adicet Bio in a report on Thursday, February 6th. HC Wainwright reiterated a &#34;neutral&#34; rating on shares of Adicet Bio in a research note on Friday, March 7th. Finally, Guggenheim restated a &#34;buy&#34; rating and set a $7.00 price target on shares of Adicet Bio in a research note on Friday, March 21st. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $7.50.</p>
<div class="lb-trans"><p>多位研究分析师最近对 ACET 股票发表了评论。StockNews.com 在周一的研究报告中将 Adicet Bio 的评级从 “卖出” 上调至 “持有”。JMP Securities 在 2 月 6 日的报告中重申了 Adicet Bio 的 “市场表现” 评级。HC Wainwright 在 3 月 7 日的研究报告中重申了 Adicet Bio 的 “中性” 评级。最后，Guggenheim 在 3 月 21 日的研究报告中重申了 “买入” 评级，并设定了 7.00 美元的目标价。三位股票研究分析师对该股票给予了持有评级，三位则给予了买入评级。根据 MarketBeat 的数据，该股票的共识评级为 “适度买入”，共识目标价为 7.50 美元。</p>
</div><p><strong>Read Our Latest Stock Report on Adicet Bio</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Adicet Bio 的最新股票报告</strong></p>
</div><h2>Adicet Bio Company Profile</h2>
<div class="lb-trans"><h2>Adicet Bio 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Adicet Bio, Inc, a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.</p>
<div class="lb-trans"><p>Adicet Bio, Inc.是一家临床阶段的生物技术公司，专注于发现和开发用于自身免疫疾病和癌症的异体伽马δ T 细胞疗法。该公司提供经过嵌合抗原受体（CARs）工程化的伽马δ T 细胞，以促进患者的持久活性。其主要产品候选药物是 ADI-001，一种表达针对 CD20 的 CAR 的异体伽马δ T 细胞疗法，目前正在进行针对自身免疫疾病和复发或难治性侵袭性 B 细胞非霍奇金淋巴瘤的 I 期临床试验。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Adicet Bio</li>
<li>Top Biotech Stocks: Exploring Innovation Opportunities</li>
<li>Why D-Wave's Project With Davidson Is a Game-Changer For Quantum</li>
<li>What is the Hang Seng index?</li>
<li>Hims &amp; Hers Stock Soars on Novo Nordisk Collaboration</li>
<li>3 Small Caps With Big Return Potential</li>
<li>Amazon's Earnings Will Make or Break the Stock's Comeback</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Adicet Bio</li>
<li>顶尖生物技术股票：探索创新机会</li>
<li>D-Wave 与 Davidson 的项目为何是量子领域的游戏改变者</li>
<li>恒生指数是什么？</li>
<li>Hims &amp; Hers 股票因与诺和诺德的合作而飙升</li>
<li>三只小型股具有巨大的回报潜力</li>
<li>亚马逊的收益将决定股票的复苏成败</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Adicet Bio Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Adicet Bio 吗？</h2>
</div><p>Before you consider Adicet Bio, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Adicet Bio 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adicet Bio wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Adicet Bio 并不在名单上。</p>
</div><p>While Adicet Bio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Adicet Bio 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Adicet Bio, Inc. (NASDAQ:ACET) 的空头头寸更新